3-Year Patient-Reported Psoriasis Outcomes for Bimekizumab, With Ron Vender, MD

Ronald Vender, MD, spoke with HCPLive about the real-world relevance of the BE RADIANT phase 3b trial, emphasizing that its design reflects the types of patients dermatologists see in everyday clinical practice.1

In this interview, Vender noted that the study’s head-to-head comparison of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, with secukinumab, an established IL-17A inhibitor, provides meaningful informtion beyond traditional efficacy endpoints.1,2

“This paper in particular was looking at patient reported outcomes in that and not necessarily efficacy in terms of [body surface area] or [Psoriasis Area and Severity Index], but we, of course, we did look at that as well,” Vender explained.

While PASI and body surface area (BSA) outcomes remain important, Vender stressed that the most compelling aspect of this analysis was its focus on patient-reported outcomes (PROs). According to Vender, rapid relief of symptoms is critical in psoriasis management. He pointed to data showing improvements in itch, skin pain, and scaling as early as the 4-week mark with bimekizumab use.

Vender underscored early attainment of PASI 0 alongside a Dermatology Life Quality Index (DLQI) score of 0 or 1 reflects not just clearance of skin, but meaningful quality-of-life improvement. At a single year and extending through 3 years, Vender emphasized the durability of patients’ responses. He acknowledged clinicians often express concern about loss of efficacy over time with biologic therapies, but the sustained symptom resolution and maintained low DLQI scores observed with continued bimekizumab therapy address that concern.

Importantly, he also discussed the subgroup of patients who switched from secukinumab to bimekizumab during the open-label extension. These patients experienced additional improvements after switching, suggesting that dual IL-17A/F inhibition may provide incremental benefit for certain individuals. However, Vender was careful to note that secukinumab remains an effective and widely used therapy; the findings represent comparative gains rather than shortcomings.

Overall, Vender framed the data as reinforcing the importance of considering both rapidity and durability of patient-centered outcomes when selecting biologic therapy for moderate to severe plaque psoriasis.

The quotes used in this summary were edited for clarity.

Vender reported support from AbbVie, Alumis, Amgen, Arcutis, Bausch, Bristol Myers Squibb, Celltrion, JAMP, Janssen, Leo, Lilly, Meiji, Novartis, Organon, Orka, Sandoz, Sun, Takeda, and UCB.

References

1. Augustin M, Feldman SR, Warren RB, et al. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. JAMA Dermatol. Published online February 18, 2026. doi:10.1001/jamadermatol.2025.6055.

2. Smith T. BE RADIANT Trial: Bimekizumab Effective for Psoriasis After 3 Years of Use. HCPLive. February 19, 2026. Accessed February 20, 2026. https://www.hcplive.com/view/be-radiant-trial-bimekizumab-effective-psoriasis-after-3-years-use.